New Insight of microRNAs & short interfering RNA in Treatment of COVID-19; a Narrative Review
Men's Health Journal,
Vol. 6 No. 1 (2022),
1 January 2022
,
Page e3
https://doi.org/10.22037/mhj.v6i1.35556
Abstract
Since 31 December 2019, the coronavirus disease 2019 (COVID-19) resulted in a state of hyperinflammation syndrome and multiorgan failure. In areas with pandemic outbreaks, despite several emerging vaccines, supportive treatments to mitigate fatality rates were required. Growing evidence suggests that several small RNAs such as microRNAs (miRNAs) and short interfering RNA (siRNA) could be candidates for the treatment of COVID-19 by inhibiting the expression of crucial virus genes. small RNAs by binding to the 3′-untranslated region (UTR) or 5′-UTR of viral RNA play an important role in COVID-19-host interplay and viral replication. In this review, the authors sought to specify the efficacy and safety of miRNAs and siRNA expressions of patients with COVID-19, which has an axial role in the pathogenesis of human diseases.
- COVID-19
- miRNAs
- siRNA
- Treatment
How to Cite
References
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894-901. https://doi.org/10.1016/j.annonc.2020.03.296.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207. https://doi.org/10.1056/NEJMoa2001316.
Cascella M , Rajnik M , Cuomo A , et al., Features, evaluation and treatment coronavirus (COVID-19). Stat pearls [internet]. Treasure Island (FL): Stat Pearls Publishing, 2020.
McGinty JC. How many people might one person with coronavirus infect? Wall Street Journal. February 14, 2020. Available from: https://www.wsj.com/articles/how-many-people-might-one-person-with-coronavirus-infect-11581676200.
Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College; 2020. Available from: https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–655. https://doi.org/10.1016/j.cell.2009.01.035.
Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA Versus miRNA as Therapeutics for Gene Silencing. Molecular Therapy—Nucleic Acids 2015;4:e252. https://doi.org/10.1038/mtna.2015.23.
Uludag H, Parent K, Montazeri Aliabadi H, Haddadi A. Prospects for RNAi Therapy of COVID-19 Front. Bioeng. Biotechnol., 2020;8:1-15. https://doi.org/10.3389/fbioe.2020.00916.
Mousavizadeh L, Ghasem S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection, 2020. https://doi.org/10.1016/j.jmii.2020.03.022.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica 2020;41:1141–1149. https://doi.org/10.1038/s41401-020-0485-4.
Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. The molecular virology of coronaviruses. J Biol Chem 2020;11;295(37):12910-12934. https://doi.org/10.1074/jbc.REV120.013930.
Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID‑19: who won and who lost? Ortolani and Pastorello Clin Mol Allergy 2020;18:17. https://doi.org/10.1186/s12948-020-00132-7.
Nemchand P, Tahir H, Mediwake R, Lee J. Cytokine storm and use of anakinra in a patient with COVID-19. Nemchand P, et al. BMJ Case Rep 2020;13:e237525. http://dx.doi.org/10.1136/bcr-2020-237525.
Mehta A, Michler T, Merkel OM. siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies? Adv Healthcare Mater 2021;2001650; 1-16. https://doi.org/10.1002/adhm.202001650.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression [letter]. Lancet 2020;395:1033-4. https://doi.org/10.1016/S0140-6736(20)30628-0.
Guan W., Ni Z., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020. https://doi.org/10.1056/NEJMoa2002032.
Banerjee AK, Blanco MR, Bruce EA, et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell 2020; 183(5): 1325-1339.-21. https://doi.org/10.1016/j.cell.2020.10.004.
Khademul Islam ABMM, Abdullah-Al-Kamran Khan M. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. Scientific Reports 2020; 10:19395. https://doi.org/10.1038/s41598-020-76404-8.
Morales L, Oliveros JC, Fernandez-Delgado R, tenOever BR, Enjuanes L, Sola I. SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology. Cell Host Microbe 2017;21(3):344–355. https://doi.org/10.1016/j.chom.2017.01.015.
Zheng Y, Zhuang MW, Han L, Zhang J, Nan ML, Zhan P, Kang D, Liu X, Gao C, Wang PH. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduction and Targeted Therapy 2020;5:299. https://doi.org/10.1038/s41392-020-00438-7.
V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS- CoV-2. Nature Reviews Microbiology 2021;19:155–170.
El-Nabi SH, Elhiti M, El-Sheekh M. Med Hypotheses. A new approach for COVID-19 treatment by micro-RNA 2020;143:110203. https://doi.org/10.1016/j.mehy.2020.110203.
Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs 2003:17:438–44.
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Frontiers in Endocrinology 2018;9:1-12. https://doi.org/10.3389/fendo.2018.00402.
Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev 2020;72(4):862-898. https://doi.org/10.1124/pr.120.019554.
Bhattacharyya P, Biswas SC. Small Non-coding RNAs: Do They Encode Answers for Controlling SARS-CoV-2 in the Future? Front. Microbiol 2020. https://doi.org/10.3389/fmicb.2020.571553.
Tak-Sum Chow J, Salmen L. Prediction and Analysis of SARS-CoV-2-Targeting MicroRNA in Human Lung Epithelium. Genes (Basel) 2020;11(9):1002. https://doi.org/10.3390/genes11091002.
Rupani H, Sanchez-Elsner T, Howarth P. MicroRNAs and respiratory diseases. Eur Resp J 2013;41:695-705. https://doi.org/10.1183/09031936.00212011.
Bartel B. Metazoan MicroRNAs. Cell 2018;173:20–51. https://doi.org/10.1016/j.cell.2018.03.006.
Felekkis K, Touvana E, Stefanou CH, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010;14(4):236–240.
Henzinger H, Barth DA, Klec C, Pichler M. Non-Coding RNAs and SARS-Related Coronaviruses. Viruses 2020;12(12):1374. https://doi.org/10.3390/v12121374.
Centa A, Fonseca AS, da Silva Ferreira SG, et al. Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients. Am J Physiol Lung Cell Mol Physiol 2021;320:L405–L412. https://doi.org/10.1152/ajplung.00457.2020.
Verma S, Dwivedy A, Kumar N, Biswal BK. Computational prediction of SARS-CoV-2 encoded miRNAs and their putative host targets. https://doi.org/10.1101/2020.11.02.365049.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315-31.
Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, West N, Zhang P, McMillan CLD, Soemardy C, Ray R, O’Meally D, Scott TA, McMillan NAJ, Morris KV. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther 2021;29(7):2219-2226.
Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL. Inhibition of SARS-CoV replication by siRNA. Antiviral Res 2005;65(1):45–48.
Chowdhury UF, Sharif Shohan MU, Hoque KI, Beg MA, Sharif Siam MK, Moni MA. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2. Genomics 2021;113(1):331-343. https://doi.org/10.1016/j.ygeno.2020.12.021.
Gatta AK, Josyula VR. Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19. Molecular Therapy: Nucleic Acids 2021;23:640-642. https://doi.org/10.1016/j.omtn.2020.12.009.
Sajid MI, Moazzam M, Cho Y, Kato S, Xu A, Way JJ, Lohan S, Tiwari RK. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. Mol Pharm 2021;18(6):2105–2121. https://doi.org/10.1021/acs.molpharmaceut.0c01239.
Ying H, Ebrahimi M, Keivan M, Khoshnam SE, Sarvenaz Salahi, Farzaneh M. miRNAs; a novel strategy for the treatment of COVID-19. Cell Biol Inter 2021;45(10):2045-2053. https://doi.org/10.1002/cbin.11653.
- Abstract Viewed: 147 times
- pdf Downloaded: 130 times